Shots:

• Sorrento is working with the FDA’s Center for Biologics Evaluation and Research to get guidance on the development of the novel I-Cel COVID-19 cellular vaccine. Post receiving FDA’s guidance- the company plans to file an IND and is expected to initiate the clinical studies in mid-2020
• Sorrento foresees its existing cGMP cell therapy manufacturing facilities will have the capacity to produce enough drug substance to meet the demand for millions of monthly doses of the vaccine if approved
• STI-6991 is an I-Cell COVID-19 cellular vaccine made up of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virus and is expected to produce both T cell and B cell immunities against SARS-CoV-2

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: Sorrento